natgillin/translations-raw huggingface dataset:
The method of claim 16, wherein the molecule is a plasmid encoding a chimeric antigen receptor comprising an extracellular antigen-binding domain that specifically binds to a target antigen, a transmembrane domain, and an intracellular signaling domain, optionally wherein the target antigen is a cancer-associated antigen and/or i) the complex or nanoparticle further comprises an siRNA; or ii) the method further comprises contacting the cell with a complex according to claim 5 or 7 or a nanoparticle according to any one of claims 6-9, wherein the complex or nanoparticle comprises an siRNA; or 
molekula je plazmid koji kodira himerni antigenski receptor, koji sadrži izvanstaničnu domenu vezanja antigena, koja se specifično veže na ciljni antigen, transmembransku domenu i unutarstaničnu signalnu domenu, opcijski je ciljni antigen antigen povezan na karcinom i/ili i) kompleksni spoj ili nanočestica nadalje sadrži siRNK; ili ii) metoda nadalje obuhvaća kontakt stanice s kompleksnim spojem prema patentnom zahtjevu 5 ili 7 ili nanočesticu prema bilo kojem od patentnih zahtjeva 6-9, pri čemu kompleksni spoj ili nanočestica sadrži siRNK; ili
The topical veterinary composition of claim 8, wherein the at least second active agent is an insect growth regulator. 
Topikalni veterinarski pripravak prema zahtjevu 8, naznačen time, da najmanje druga djelatna tvar je regulator rasta kukaca.
The method according to claim 21, wherein said predeterminable indicia is a design or an image. The method according to claim 21, wherein a second surface of said sheet or web, opposite to said first surface, is exposed to said magnetic field of the surface of the body of permanent-magnetic material. 
Postupak sukladno jednom od patentnih zahtjeva 7 ili 8, naznačen time, da se donja površina navedenog lista ili tkanine, koja se nalazi suprotno od navedene otisnute ili premazane gornje površine, izlaže djelovanju navedenog magnetskog polja površine na kojoj se nalaze oznake tijela od magnetiziranog permanentno magnetskog materijala.
a natural or artificial body of water; selected from the group consisting of a lake, sea, estuary, dam, lagoon, spa, pool, pond and reservoir; and/or 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se vodenu površinu bira iz skupine koju čine jezero, more, riječno ušće, akumulacijsko jezero, laguna, toplice, bazen, bara i rezervoar.
The metastin derivative according to claim 22 or 23, or a salt thereof, for use as an agent for preventing or treating hormone-dependent cancer. 
Derivat mctastina proma zahtjevu 22 ili 23, ili njegova sol, naznačen(a) time, da sc koristi kao sredstvo za prevenciju ili liječenje raka ovisnog o hormonima.
The reaction of the compound of Formula IX with the compound of Formula XVc may be carried out using analogous conditions to those described in process (j) above, followed by removal of the protecting group under standard conditions. 
Reakcija izmeđa spoja prikazanog Formulom IX i spoja prikazanog Formulom XVc može se provesti pod uvjetima analognim uvjetima navedenim gore za postupak (j), i popratiti uklanjanjem zaštitne skupine pod standardnim uvjetima.
The diabody molecule of claim 6, wherein the molecule additionally comprises a third polypeptide chain and a fourth polypeptide chain, the additional polypeptide chains being covalently bonded to one another, wherein: 
Molekula diatijela prema zahtjevu 1 ili 2, naznačena time što molekula diatijela dodatno obuhvaća treći polipeptidni lanac i četvrti polipeptidni lanac, te su treći i četvrti polipeptidni lanci kovalentno vezani jedan na drugi, pri čemu:
a is an integer from 1 to 2; is selected from the group consisting of and wherein b is an integer from 0 to 2; and wherein c is 0; 
a je cijeli broj od 1 do 2; [image] je odabran iz skupine koju sačinjavaju [image] [image] i [image] pri čemu b je cijeli broj od 0 do 2; i pri čemu c je 0;
Also provided is a use of the compound of the invention and/or at least one pharmaceutically acceptable salt thereof in the preparation of a medicine for treating cancer. In a preferred embodiment, the cancer is chosen from lung cancer, head and neck cancer, colorectal cancer, pharynx cancer, epidermoid cancer, and pancreatic cancer. 
Spoj ifili najmanje jedna odgovarajuća farmaceutski prihvatljiva sol za upotrebu prema patentnom zahtjevu 3, naznačeno time da je karcinom odabran od sljedećih: karcinom pluća, karcinom glave i vrata, karcinom kolorektuma, karcinom ždrijela, epidermoidni karcinom i karcinom pankreasa.
wherein W1 represents a suitable leaving group and wherein R1, R3 to R7, p, q and X are defined as in claim 1; reacting an intermediate of formula (III) with an intermediate of formula (IV) in the presence of a suitable coupling agent, in the presence of a suitable solvent and optionally in the presence of a suitable base, 
(a) pri čemu W, predstavlja pogodnu odlaznu skupinu i pri čemu su R', R* do R/, p, q i X kako je definirano u patentnom zahtjevu 1; reakciju intermedijera formule (III) sa intermedijerom formule (IV) u prisutnosti pogodnog sredstva za povezivanje, pogodnog otapala i po izboru u prisutnosti pogodne baze, 1
The pharmaceutical composition of claim 13, wherein said compound of formula I is selected from the group consisting of: 
Spoj prema zahtjevu 1, naznačen time što je izabran iz skupine koju sačinjavaju
The composition of embodiment 24, comprising a pharmaceutically acceptable carrier or excipient. 
Sastav koja obuhvaća stanicu prema zahtjevu 8, koja opcionalno obuhvaća farmaceutski prihvatljivi nosač ili pomoćnu tvar.
A conjugated nucleic acid molecule of the following formula: 
PATENTNI ZAHTJEVI 1. - Konjugirana molekula nukleinske kiseline, naznačena time što ima sljedeću formulu:
The filtering apparatus according to claim 6, wherein each of the at least two compartments is in communication with a hopper for collecting the particulate. A method for regenerating a filtering apparatus comprising: 
Uređaj za filtriranje (1) prema jednom ili više od prethodnih zahtjeva, naznačen time što je svaki od odjeljaka povezan, u svom donjem dijelu, s lijevkom (100) za skupljanje čestica.
The glove according to claim 3, wherein said means for detecting pH is a mixture of Methylorange and Bromocresol Green in a 1:5 (w/w) ratio. 
Rukavica u skladu s patentnim zahtjevom 3, naznačena time što je navedeno sredstvo za određivanje pH smjesa metiloranža i bromkrezol zelenog u omjeru od 1:5 (tež./tež.).
a therapeutically effective amount of valganciclovir hydrochloride; and 
(a) terapeutski učinkovitu količinu valganciklovir-hidroklorida; 1
One such method comprises (a) selecting a first antibody that binds to an antigen of interest with a desired affinity, (b) modifying an immunoglobulin light chain nucleotide sequence of the first antibody to comprise a substitution of at least one non-histidine codon with a histidine codon, (c) expressing an immunoglobulin heavy chain of the first antibody and the modified immunoglobulin light chain in a cell, and (d) selecting a second antibody expressed in the cell that retains a desired affinity for the antigen of interest at neutral pH and displays reduced binding to the antigen of interest at an acidic pH. 
Metoda za dobivanje antitijela koje izražava vezivanje ovisno o pH vrijednosti za interesni antigen koja se sastoji od: imunizacije glodavca prema bilo kojem zahtjevu od 1 do 11 ili glodavca dobivenog pomoću metode prema zahtjevu 12 s interesnim antigenom; 1 dobivanja B stanice koja izražava antitijelo koje se vezuje za interesni antigen sa željenim afinitetom pri neutralnoj pH vrijednosti uz ispoljavanje smanjenog vezivanja za interesni antigen pri kiseloj pH vrijednosti 1 opcionalno (a) korištenja B stanice za dobivanje hibridoma ili (b) izoliranja DNK koja šifrira antitijelo iz B stanice ili hibridoma i umetanje DNK u vektore ekspresije 1 transfektiranje vektora u stanicu domaćina.
The compound A pharmaceutical composition comprising an effective amount of the compound according to claim 1 and a pharmaceutically acceptable carrier. 
Farmaceutska kompozicija koja sadrži efikasnu količinu spoja prema bilo kojem od patentnih zahtjeva 1-10, ili njegove farmaceutski prihvatljive soli, 1 farmaceutski prihvatljiv nosač.
After stirring for 5 minutes methylene chloride (51) was added and stirring was continued for 10 min. 
Poslije miješanja 5 minuta dodaje se metilen klorid (5 1) 1 miješanje je nastavljeno 10 min.
Power unit according to Claim 2, characterised in that it is equipped with a speed-increasing gearbox of which the low-speed member is kinematically linked to the driving train, and of which the high-speed member is connected to a load. 
Pogonski agregat prema jednom od zahtjeva 1-3, naznačen time da je opremljen s prijenosnikom za ubrzanje okretaja, čiji se članak za spore okretaje sastoji od navedenog zupčanika (4), a čiji je članak za brze okretaje spojen na opterećenje (21).
Another aspect of the invention is a metabolite of the compound or the pharmaceutical composition according to any one of paragraphs [0033]-[0138]. 
Spoj ili farmaceutski sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak želudca.
The preferred glycine-rich linker comprises the sequence: Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser (SEQ ID NO:8). 
Heterologni fuzijski protein u skladu s patentnim zahtjevom 2, naznačen time što spojnica sadrži slijed SEQ ID NO:8.
The process according to claim 28 comprising carrying out the cleavage in step a) using a combination of both chemical and enzymatic treatments. 
Postupak u skladu s patentnim zahtjevom 23 obuhvaća provođenje cijepanja u koraku a) koristeći kombinaciju i kemijskog i enzimskog tretiranja.
Utilities and Combinations 
Primjene i kombinacije
The apparatus according to Claim 3, wherein the stirrer is shaped in the form chosen from a straight cylindrical bar, a cross cylindrical bar and a circular plate. 
Uređaj sukladno patentnom zahtjevu 1, pri čemu je mješalica (32) oblikovana u obliku odabranom od ravne cilindrične šipke, križne cilindrične šipke i kružne ploče.
The drive roller as claimed in claim 1, wherein a central area of the carrier element module which is bounded by the groove is in the form of a flange. 
Pogonski valjak (1, 18) prema jednom od zahtjeva 1 do 3, naznačen time, da je centralno područje nosivog elementa (4, 6, 21, 25, 27, 29), koje je ograničeno pomoću žlijeba (30), konstruirano kao prirubnica (31).
The pharmaceutical composition can be formulated employing conventional solid or liquid vehicles or diluents and pharmaceutical additives of a type appropriate to the mode of desired administration, such as pharmaceutically acceptable carriers, excipients, binders and the like. 
Farmaceutska kompozicija može biti formulirana korištenjem uobičajenih čvrstih ili tekućih nosača ili razblaživača i farmaceutskih aditiva tipa koji odgovara režimu željene primjene, kao što su farmaceutski prihvatljivi nosači, inertni punitelji, vezujuća sredstva i slično.
In case of reinfection, this was treated with a further standard miconazole treatment and the follow up with ascorbic acid was continued immediately after confirmation of microbiological eradication. 
U slučaju ponovne infekcije, ona je liječenja daljnjim standardnim tretmanom mikonazolom te je slijedila askorbinska kiselina odmah nakon potvrde mikrobiološkog iskorjenjivanja.
amplifying cell-free (cfDNA) from a blood sample obtained from the recipient 24 hrs or less after transplantation of graft material from the donor; 
(b) pojačavanja acelularne (cfDNK) iz uzorka seruma ili plazme dobivenog od primatelja 24 sata ili manje nakon presađivanja materijala presatka od darivatelja;
The method of item 32, wherein the skin disease or disorder is alopecia. 
Farmaceutski pripravak za uporabu prema zahtjevu 32, naznačen time da je kožna bolest ili poremećaj alopecija.
The method according to claim 1, wherein the targeting endonuclease is a zinc finger nuclease. The method according to claim 1, wherein the polynucleotide is stably integrated randomly in the genome of the plant cell. The method according to claim 1, wherein the polynucleotide is stably integrated at one or more known target sites in the genome of the plant cell. 
Postupak prema bilo kojem od zahtjeva 1 do 4, naznačen time, da je molekula nukleinske kiseline stabilno integrirana nasumice u genomu biljne stanice, ili je stabilno integrirana u jedno ili više poznatih ciljnih mjesta u genomu biljne stanice, ili je stabilno integrirana u amplificirano područje kromosoma ili minikromosoma.
in the presence of a coupling catalyst to form the compound of Formula IId, wherein X3 is chloro, bromo, or iodo. 
N lIc u prisutnosti paladijevog (II) diacetata da se dobije spoj s formulom IId; pri čemu X; je klor, brom, ili jod.
The substrate specificity, sodium dependence, and localization of SGLT2 are consistent with the properties of the high capacity, low affinity, sodium-dependent glucose transporter previously characterized in human cortical kidney proximal tubules. 
Specifičnost za supstrat, ovisnost od natrija, i lokalizacija SGLT2 su u skladu sa svojstvima visokog kapaciteta, niskog afinitcta, natrij-zavisnog transportera glukoze koji je prethodno okarakteriziran u humanim kortikalnim bubrežnim proksimalnim tubulama.
A compound according to claim 1, wherein the compound of formula (I) is in solid crystalline form having the X-ray powder diffraction pattern substantially as shown in Figure 2. 
Spoj prema zahtjevu 1, naznačen time da spoj s formulom (1) u krutom kristalnom obliku ima uzorak difrakcije X-zraka na prahu uglavnom kako je prikazano na slici 2.
Method according to claim 2, wherein pickling is made by spraying the strip with an aqueous solution of 5 to 30 g/l, preferably 8 to 15 g/l, of a first initial solution comprising 25 to 50 wt.-% sulphuric acid and 5 to 15 wt.-% non ionic tenside, and 0.1 to 10 g/l, preferably 1 to 3 g/l, of a second initial solution comprising 5 to 7 wt.-% hydrofluoric acid. 
Postupak prema zahtjevu 2, naznačen time, da se luženje vrši putem sprejanja trake s vodenom otopinom od 5 do 30 g/l, poželjno od 8 do 15 g/l prve početne otopine koja sadrži od 25 do 50 masenih % sumporne kiseline 1 od 5 do 15 masenih % ne-ionskog tenzida, te od 0,1 do 10 g/l, poželjno od 1 do 3 g/l druge početne otopine koja sadrži od 5 do 7 masenih % fluorovodične kiseline.
The mooring buoy of claim 4, wherein the controller is configured to activate the RF communication device to receive the vessel ID upon detecting via the movement sensor that the buoy is in a mooring position, and the controller is further configured to compare the received booking vessel ID with the received vessel ID to determine whether the vessel ID is associated with the mooring buoy. 
Plutača za privez (101) prema zahtjevu 4, naznačena time što je kontroler postavljen da aktivira RF komunikacijski uređaj (403) radi prijema ID-a plovila nakon otkrivanja putem senzora kretanja da je plutača za privez (101) u položaju za privez, a kontroler je nadalje postavljen da uspoređuje primljeni rezervacijski ID plovila s primljenim ID-om plovila radi određivanja da li je ID plovila povezan s plutačom za privez (101).
The invention also provides a pumping system for use in the system for wastewater treatment of the invention. The pumping system comprising: 
Sustav za pumpanje za uporabu u sustavu za preradu otpadne vode sukladno bilo kojem od patentnih zahtjeva 5 do 14 obuhvaća:
Proteins bind to the metal ions through unoccupied coordination sites and are immobilized on the column. 
Proteini se vezuju na metalne ione pomoću praznih koordinacijskih mjesta te se time imobiliziraju na kolonu.
The compound or a salt thereof, or a solvate of these according to claim 1, wherein R1 is a hydrogen atom or a methyl group. 
Spoj ili njegova sol ili solvat u skladu s patentnim zahtjevom 1, naznačen time, da je R1 vodikov atom ili metilna skupina.
A method according to claim 1, comprising performing the method with a steam-treatment apparatus comprising a first and a second steam-treatment unit arranged to use superheated steam, and by transferring the material treated in the first steam-treatment unit into the second steam-treatment unit. 
Metoda u skladu s bilo kojim od prethodnih patentnih zahtjeva 1 do 12, karakterizirana izvođenjem metode s uređajem za tretiranje parom koja obuhvaća prvu i drugu jedinicu za tretiranje parom postavljene za uporabu superzagrijane pare, 1 prijenosom materijala tretiranog u prvoj jedinici za tretiranje parom u drugu jedinicu za tretiranje parom.
wherein the lysis buffer is selected from the group consisting of guanidine thiocyanate, guanidine hydrochloride, EDTA, Tris, detergent, polyol, monovalent salt containing group IA cation, divalent salt containing group IIA cation, protein digesting enzyme and combinations thereof, 
HR P20171823 T1 sadržavati i ureu, poliol, jednovalentnu sol, koja sadrži kation iz skupine IA i/ili dvovalentnu sol, koja sadrži kation iz skupine IIA i proteolitički enzim.
a structure (F) with at least four frame members (H 1, H 2, H 3, H 4); 
okvirnu konstrukciju (F) s najmanje četiri okvirna elementa (H1, H2, H3, H4);
The composition of claim 1, comprising the DNA-targeting RNA, wherein the targeter-RNA and/or the activator-RNA comprises one or more of: a phosphorothioate, an inverted polarity linkage, an abasic nucleoside linkage, a locked nucleic acid (LNA), a 2′-O-methoxyethyl modified sugar moiety, a 2′-O-methyl modified sugar moiety, a 2′-O-(2-methoxyethyl) modified sugar moiety, a 2′-fluoro modified sugar moiety, a 2′-dimethylaminooxyethoxy modified sugar moiety, a 2′-dimethylaminoethoxyethoxy modified sugar moiety, a peptide nucleic acid (PNA), a morpholino nucleic acid, and a cyclohexenyl nucleic acid (CeNA). 
Sastav prema bilo kojem od zahtjeva 1, ili 6 do 10, ili 12 do 13, ili postupak u skladu s bilo kojim od zahtjeva 2 do 4, ili 6 do 13, ili garnitura prema bilo kojem od zahtjeva 5 do 10, ili 12 do 13, naznačen/a time, da RNK koja cilja na DNK, obuhvaća jednu ili više modificiranih nukleobaza, modificiranih strukturnih okosnica ili ne-prirodnih internukleozidnih lančanih spojeva, modificirani dio molekule šećera, zaključanu nukleinsku kiselinu (LNA), ili peptidnu nukleinsku kiselinu.
A method and a device for producing a semi-product for a core of a building panel, such as a floorboard, is shown in a side view in FIG. 
HR P20182105 T1 PATENTNI ZAHTJEVI Postupak proizvodnje poluproizvoda za građevnu ploču, kao što je podna ploča, naznačen time što postupak obuhvaća:
The composition for use according to any one of claims 1-7, wherein the size of the transfer vehicle is less than 250 nm, 175 nm, 150 nm, 125 nm, 100 nm, 75 nm, 50 nm, 25 nm or 10 nm. 
HR P20191338 T1 Sastav za upotrebu prema bilo kojem od patentnih zahtjeva 1-11, gdje je veličina nosača za prijenos manja od 250 nm, 175 nm, 150 nm, 125 nm, 100 nm, 75 nm, 50 nm, 25 nm ili 10 nm.
a nucleic acid encoding a fusion protein between an essential protein and a destabilizing protein, wherein the essential protein is selected from the group consisting of IE1/2, UL51, UL52, UL79 and UL84 wherein the destabilizing protein is either FK506-binding protein (FKBP) or an FKBP derivative, wherein the FKBP derivative is FKBP comprising one or more amino acid substitutions selected from the group consisting of: F15S, V24A, H25R, F36V, E60G, M66T, R71G, D100G, D100N, E102G, K105I and L106P, and wherein the wild type essential protein is no longer present. 
(b) nukleinsku kiselinu koja kodira fuzijski protein između esencijalnog proteina i destabilizirajućeg proteina, pri čemu je esencijalni protein izabran iz grupe koja se sastoji od IE1/2, ULS51, UL52, UL79 1 UL84, pri čemu, destabilizirajući protein je FK506-vezujući protein (FKBP) ili FKBP derivat, pri čemu, FKBP derivat je FKBP koji sadrži jednu ili više aminokiselinskih supstitucija izabranih iz grupe koja se sastoji od: F15S, V24A, H25R, F36V, E60G, M66T, R71G, D100G, D100N, E102G, K1051I 1 L106P, i pri čemu divlji tip esencijalnog proteina nije više prisutan.
at least 80% of the cells in the population express detectable levels of CD181 (C-X-C chemokine receptor type 1; CXCR1), 
(vili) najmanje 80 % stanica u populaciji na svojoj površini izražava uočljive razine CDI81 (C-X-C kemokin receptor tipa 1; CXCRI),
Method according to claim 12, wherein a lid member (2) is placed, preferably removably placed on a container opening (6) of the container (1) to close the container (1). 
Postupak u skladu s patentnim zahtjevom 12 ili 13, naznačen time što se element za zatvaranje (2), po mogućnosti uklonjivo, stavi na otvor (6) spremnika (1) kako bi se zatvorilo spremnik (1).
CBA is a cell binding agent, which is the anti-DLL3 antibody M; 
CBA je sredstvo za vezanje stanice koje je protutijelo anti-DLL3;
The stated technical problem can be solved by the use of magnetic optically variable pigment in a printing ink, in conjunction with an orientation of the magnetic optically variable pigment particles in the printing process through the application of appropriate magnetic fields. 
Navedeni tehnički problem može se riješiti uporabom magnetskog optički varijabilnog pigmenta u tiskarskoj tinti, zajedno s usmjeravanjem čestica magnetskog optički varijabilnog pigmenta u postupku tiskanja primjenom odgovarajućih magnetskih polja.
The medicament of claim 11 or 12, which is an agent for the prophylaxis or treatment of circulatory diseases. 
Lijek u skladu sa zahtjevom 31, naznačen time, da se koristi za profilaksu ili liječenje oboljenja u kojima je sadržana inzulinska rezistencija.
The method of any one of the previous claims, wherein the antibody or antigen binding fragment thereof further comprises a human k light chain constant region. 
Protutijelo ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time što protutijelo ili njegov ulomak koji veže antigen nadalje sadrži humanu x konstantnu regiju lakog lanca.
Transforms from monoclinic to orthorhombic phase at 490° C. with a volume expansion of 12%. 
Transformira se iz monoklinske i ortorombsku fazu pri 490 "€ s ekspanzijom volumena od 12%.
converting a compound of formula [52] to a compound of formula [I-3-2] 
a? Postupak dobivanja spoja formule [1-3-2] gdje
mixing a B2-adrenergic agonist with the microfine excipient and sieving the resulting mixture; 
(ii) miješanje B2-adrenergičkog agonista s mikrofinim ekscipijensom i prosijavanje nastale smjese;
Use according to any one of the preceding claims, characterized in that said 2-((1-methylpropyl)amino)ethanol is added to said suspension in an amount of from 1000 to 5000 mg, and more preferably of 1300 to 2000 mg, per liter of the aqueous phase of said suspension. 
Uporaba u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakterizirana na način da je navedeni 2-((1- metilpropil)amino)etanol dodan u navedenu otopinu u količini od 1000 do 5000 mg, poželjnije od 1300 do 2000 mg, po litri vodene faze navedene otopine.
The data shown are a representative example of one of the duplicates. 
fznijeti podaci reprezenfalivan su primjer za jadan od duplikata.
The TGFß antagonist of any one of the preceding claims wherein said TGFß antagonist is co-administered with capecitabine, and ixabepilone. 
Antagonist TGFB za uporabu u skladu sa zahtjevom 1, naznačen time što se navedeni antagonist TGFB primjenjuje zajedno s kapecitabinom i iksabepilonom.
The compound according to claim 1 or 2 or a salt thereof, or a hydrate or a solvate thereof, wherein R2 is a C1-6 alkyl group substituted with 1 to 3 substituents selected from the substituent group 4, and the substituent group 4 is a group consisting of hydroxy group, and a group represented by the formula -NR17R18. 
Spoj u skladu s patentnim zahtjevom 1 ili 2 ili sol istog ili hidrat ili solvat istog, naznačen time, da R2 je C1-6 alkilna skupina supstituirana s 1 do 3 supstituenta odabrana od supstituenta skupine 4, a supstituent skupine 4 je skupina koja se sastoji od hidroksi skupine i skupine predstavljene formulom -NR17R18.
wherein: R2 is hydrogen; and R1 and R3 together with the atoms to which they are attached form a carbocyclic ring having from 4 to 6 ring atoms. For example, Q1 may be: 
Bi parna da iu din" MHRS pri čemu: R> je vodik; i R, i R3 zajedno s atomima za koje su vezani tvore karbociklički prsten koji ima od 4 do 6 atoma prstena.